Xcellerated T CellsTM in Patients With Multiple Myeloma

Summary

This trial is a phase II, randomized study of patients with multiple myeloma. All patients will receive Xcellerated T Cells, with or without prior fludarabine therapy. 15 patients in each study arm will be followed for 6 months.

Timeline

Start

2003-11

Primary completion

—

Completion

2004-06

Drugs

Indications